Endocrinología: avances 2019/2020. Introducción

12.10.2020
Endokrynologia – postępy 2019/2020
prof. Andrzej Lewiński (MD, PhD)

Cómo citar: Lewiński A., Endokrynologia – postępy 2019/2020, Med. Prakt., 2020, 6: 78-89

Siglas y abreviaturas: anti-TPO — anticuerpos antitiroperoxidasa, anti-TSHR — anticuerpos contra el receptor de TSH, ATA — American Thyroid Association, BAAF — biopsia por aspiración con aguda fina, BPA — bisfenol A, CC — características clave, CMT — cáncer medular de tiroides, CP — cáncer de paratiroides, CPT — cáncer papilar de tiroides, CTD — cáncer de tiroides diferenciado, CTLA-4 (cytotoxic T lymphocyte 4 antigen) — antígeno 4 del linfocito T citotóxico, DHC — deficiencia de la hormona del crecimiento, DMO — densidad mineral ósea, DPP4 — dipeptidil peptidasa-4, EAA — esteroides anabólicos androgénicos, EDC (endocrine disrupting compound) — interruptor endocrino, EGB — enfermedad de Graves-Basedow, ESMO — European Society for Medical Oncology, ETA — European Thyroid Association, FDA (Food and Drug Administration) — Administración de Alimentos y Medicamentos estadounidense, (F)T3 — triyodotironina (libre), (F)T4 — tiroxina (libre), GLP-1 — péptido similar al glucagón tipo 1, HAART (highly active antiretroviral therapy) — terapia antirretroviral altamente activa, HC — hormona del crecimiento o somatotropina, hCG (human chorionic gonadotropin) — gonadotropina coriónica humana, HCRH — hormona del crecimiento recombinante humana, HiperP — hiperparatiroidismo primario, HipoPT — hipoparatiroidismo, HS — hipotiroidismo subclínico, IGF-1 — factor de crecimiento insulínico tipo 1, IMC — índice de masa corporal, L-T4 — levotiroxina, MKI (multikinase inhibitors) — inhibidores de la multicinasa, NEM-1 — neoplasia endocrina múltiple tipo 1, NIFTP (noninvasive follicular thyroid neoplasm with papillary-like nuclear features) — neoplasia folicular de tiroides no invasiva con núcleos que se asemejan al carcinoma papilar, PD-1 (programmed death receptor 1) — proteína de muerte celular programada 1, PTHrP (parathyroid hormone related peptide) — proteína relacionada con la hormona paratiroidea, PTI — prueba de tolerancia a la insulina, RAI — radioterapia con yodo radiactivo, RSCa — receptor sensible al calcio, SAHOS — síndrome de apnea e hipopnea obstructivas del sueño, SERM (selective estrogen receptor modulators) — moduladores selectivos de los receptores de estrógeno, SGLT-2 (sodium glucose cotransporter 2) — cotransportador sodio-glucosa tipo 2, SHBG (sex hormone binding globulin) — globulina fijadora de hormonas sexuales, SPECT-CT (single photon emission computed tomography – computed tomography) — tomografía computarizada por emisión de fotón único combinada con tomografía computarizada, TCMH — trasplante de células madre hematopoyéticas, TDSH — trastorno del deseo sexual hipoactivo, TFGe — tasa de filtración glomerular estimada, TMO — trasplante de médula ósea, TRH — terapia de reemplazo hormonal, TRI — terapia de reconstitución inmune, TSH — tirotropina, VIH — virus de inmunodeficiencia humana

Nota: La revisión de las publicaciones abarca el periodo comprendido entre el 10/03/2019 y el 06/03/2020.

Bibliografía:

1. Giustina A., Barkan A., Beckers A. y cols., A consensus on the diagnosis and treatment of acromegaly comorbidities: an update, J. Clin. Endocrinol. Metab., 2019; 105: pii: dgz096; doi: 10.1210/clinem/dgz096
2. Melmed S., Casanueva F.F., Klibanski A. y cols., A consensus on the diagnosis and treatment of acromegaly complications, Pituitary, 2013; 16: 294–302
3. Bolanowski M., Ruchała M., Zgliczyński W. y cols., Akromegalia – nowe spojrzenie na pacjenta. Polskie propozycje postępowania diagnostyczno-terapeutycznego w akromegalii w świetle aktualnych doniesień, Endokrynol. Pol., 2019; 70: 2–18
4. Yuen K.C.J., Biller B.M.K., Radovick S. y cols., American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care, Endocr. Pract., 2019; 25: 1191–1232
5. Lewiński A., Smyczyńska J., Stawerska R. y cols., National program of severe growth hormone deficiency treatment in adults and adolescents after completion of growth promoting therapy, Endokrynol. Pol., 2018; 69: 468–524
6. Alexander E.K., Pearce E.N., Brent G.A. y cols., 2017 guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum, Thyroid, 2017; 27: 315–389
7. Stagnaro-Green A., Dong A., Stephenson M.D., Universal screening for thyroid disease during pregnancy should be performed, Best Pract. Res. Clin. Endocrinol. Metab., 2019; 6: 101–320
8. Hubalewska-Dydejczyk A., Lewiński A., Milewicz A. y cols., Management of thyroid diseases during pregnancy, Endokrynol. Pol., 2011; 62: 362–381
9. Ghassabian A., Pierotti L., Basterrechea M. y cols., Association of exposure to ambient air pollution with thyroid function during pregnancy, JAMA Netw. Open, 2019; 2: e1912 902; doi: 10.1001/jamanetworkopen.2019.12 902
10. Bekkering G.E., Agoritsas T., Lytvyn L. y cols., Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline, BMJ, 2019; 365: l2006; doi: 10.1136/bmj.l2006
11. Mooijaart S.P., Du Puy R.S., Stott D.J. y cols., Association between levothyroxine treatment and thyroid-related symptoms among adults aged 80 years and older with subclinical hypothyroidism, JAMA, 2019; 1–11; doi: 10.1001/jama.2019.17 274
12. Muller I., Moran C., Lecumberri B. y cols., 2019 European Thyroid Association guidelines on the management of thyroid dysfunction following immune reconstitution therapy, Eur. Thyroid J., 2019; 8: 173–185
13. Burch H.B., Drug effects on the thyroid, N. Engl. J. Med., 2019; 381: 749–761
14. Filetti S., Durante C., Hartl D. y cols., ESMO Guidelines Committee. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann. Oncol., 2019; 30: 1856–1883
15. Haugen B.R., Alexander E.K., Bible K.C. y cols., 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer, Thyroid, 2016; 26: 1–133
16. Fugazzola L., Elisei R., Fuhrer D. y cols., 2019 European Thyroid Association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer, Eur. Thyroid J., 2019; 8: 227–245
17. Tuttle R.M., Ahuja S., Avram A.M. y cols., Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association, Thyroid, 2019; 29: 461–470
18. Guldvog I., Reitsma L.C., Johnsen L. y cols., Thyroidectomy versus medical management for euthyroid patients with Hashimoto disease and persisting symptoms: a randomized trial, Ann. Intern. Med., 2019; 170: 453–464
19. Khan A.A., Koch Ch.A., Van Uum S. y cols., Standards of care for hypoparathyroidism in adults: a Canadian and international consensus, Eur. J. Endocrinol., 2019; 180: P1–P23
20. Khan A.A., Clarke B., Rejnmark L., Brandi M.L., Management of endocrine disease: Hypoparathyroidism in pregnancy: review and evidence-based recommendations for management, Eur. J. Endocrinol., 2019; 180: R37–R44
21. Bollerslev J., Schalin-Jantti C., Rejnmark L. y cols., Management of endocrine disease: unmet therapeutic, educational and scientific needs in parathyroid disorders, Eur. J. Endocrinol., 2019; 181: P1–P19
22. Eastell R., Rosen C.J., Black D.M. y cols., Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline, J. Clin. Endocrinol. Metab., 2019; 104: 1595–1622
23. Davis S.R., Baber R., Panay N. y cols., Global consensus position statement on the use of testosterone therapy for women, J. Clin. Endocrinol. Metab., 2019; 104: 4660–4666
24. Kanakis G.A., Nordkap L., Bang A.K. y cols., EAA clinical practice guidelines – gynecomastia evaluation and management, Andrology, 2019; 7: 778–793
25. La Merrill M.A., Vandenberg L.N., Smith M.T. y cols., Consensus on the key characteristics of endocrine-disrupting chemicals as a basis for hazard identification, Nat. Rev. Endocrinol., 2020; 16: 45–57
26. Fountas A., Van Uum S., Karavitaki N., Opioid-induced endocrinopathies, Lancet Diabetes Endocrinol., 2020; 8: 68–80

Más